Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study
暂无分享,去创建一个
Hilkka Soininen | Miia Kivipelto | Jaakko Tuomilehto | Bengt Winblad | Tiina Laatikainen | B. Winblad | H. Soininen | M. Kivipelto | J. Tuomilehto | T. Ngandu | T. Laatikainen | Tiia Ngandu
[1] Daniel W. Jones,et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.
[2] A Hofman,et al. Gender differences in the incidence of AD and vascular dementia , 1999, Neurology.
[3] T. Teramoto,et al. Determination by PCR-RFLP of apo E genotype in a Japanese population. , 1993, The Journal of laboratory and clinical medicine.
[4] C M Burchfiel,et al. Metabolic Cardiovascular Syndrome and Risk of Dementia in Japanese-American Elderly Men: The Honolulu-Asia Aging Study , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[5] Kenneth Rockwood,et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. , 2002, Archives of neurology.
[6] A. Hofman,et al. Antihypertensive drugs and incidence of dementia: the Rotterdam Study , 2001, Neurobiology of Aging.
[7] P. Poole‐Wilson,et al. [Prevention of coronary disease in clinical practice. Recommendations of the Task-Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension]. , 1995, Annales de cardiologie et d'angeiologie.
[8] R. D'Agostino,et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.
[9] B. Winblad,et al. Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD , 2003, Neurology.
[10] J. Tuomilehto,et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial , 1998, The Lancet.
[11] J. Saczynski,et al. The Honolulu-Asia Aging Study , 2007 .
[12] Deborah Gustafson,et al. An 18-year follow-up of overweight and risk of Alzheimer disease. , 2003, Archives of internal medicine.
[13] M. Prince,et al. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults , 1996, BMJ.
[14] GerdAssmann,et al. Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study , 2002 .
[15] D. Jolley,et al. Cost benefits of a medically supervised day treatment program for patients with Alzheimer's disease and other forms of dementia , 1989 .
[16] R. Havlik,et al. Midlife blood pressure and dementia: the Honolulu–Asia aging study☆ , 2000, Neurobiology of Aging.
[17] G. Chatellier,et al. The Framingham prediction rule is not valid in a European population of treated hypertensive patients , 2002, Journal of hypertension.
[18] Jaakko Tuomilehto,et al. The diabetes risk score: a practical tool to predict type 2 diabetes risk. , 2003, Diabetes care.
[19] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[20] E. Vartiainen,et al. Change in risk factors for coronary heart disease during 10 years of a community intervention programme (North Karelia project). , 1983, British medical journal.
[21] M W Knuiman,et al. Prediction of coronary heart disease mortality in Busselton, Western Australia: an evaluation of the Framingham, national health epidemiologic follow up study, and WHO ERICA risk scores. , 1997, Journal of epidemiology and community health.
[22] François Gueyffier,et al. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials , 2001, BMJ : British Medical Journal.
[23] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[24] A. Hofman,et al. Non-insulin-dependent Diabetes Mellitus (niddm) Association of Diabetes Mellitus and Dementia: the Rotterdam Study , 2022 .
[25] J. Virtamo,et al. Changes in coronary risk factors during comprehensive five-year community programme to control cardiovascular diseases (North Karelia project). , 1979, British medical journal.
[26] I. U. Haq,et al. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men , 1999, Heart.
[27] P. Poole‐Wilson,et al. Prevention of coronary heart disease in clinical practice , 1994 .
[28] A. Menotti,et al. Prediction of coronary heart disease in Europe. The 2nd report of the WHO-ERICA Project. ERICA Research Group. , 1991, European heart journal.
[29] R. Jung,et al. Controlled trial of effect of documented cardiovascular risk scores on prescribing , 2003, BMJ : British Medical Journal.
[30] L. Kuller,et al. Systolic Hypertension in the Elderly Program (SHEP) , 1986, Journal of the American Geriatrics Society.
[31] A. Hofman,et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.
[32] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.
[33] B. Lernfelt,et al. 15-year longitudinal study of blood pressure and dementia , 1996, The Lancet.
[34] H Jick,et al. Statins and the risk of dementia , 2000, The Lancet.
[35] H. Soininen,et al. Midlife vascular risk factors and late-life mild cognitive impairment , 2001, Neurology.
[36] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[37] Neil Chapman,et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. , 2003, Archives of internal medicine.
[38] Jaakko Tuomilehto,et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002 .
[39] H. Tunstall-Pedoe,et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.
[40] J Tuomilehto,et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study , 2001, BMJ.
[41] Hilkka Soininen,et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. , 2005, Archives of neurology.
[42] H Tunstall-Pedoe,et al. The Dundee coronary risk-disk for management of change in risk factors. , 1991, BMJ.
[43] Laura Fratiglioni,et al. Worldwide Prevalence and Incidence of Dementia , 1999, Drugs & aging.
[44] A. Folsom,et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. , 2003, Journal of clinical epidemiology.
[45] E. Vartiainen,et al. Twenty-year trends in coronary risk factors in north Karelia and in other areas of Finland. , 1994, International journal of epidemiology.